Transpresentation of interleukin-15 by IL-15/IL-15Ra mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44123-44133

  Van den Bergh, Johan ^a   Willemen, Yannick ^a   Lion, Eva ^a   Van Acker, Heleen ^a   De Reu, Hans ^a   Anguille, Sébastien ^a   Goossens, Herman ^a   Berneman, Zwi ^a   Van Tendeloo, Viggo ^a   Smits, Evelien ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Dendritic cells; IL 15 receptor a; Immune response; Immunity; Immunology and microbiology section; Interleukin 15 transpresentation; Mrna elektroporation; Natural killer cells

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; MESSENGER RNA; PERFORIN; CANCER VACCINE; GRANZYME; GZMB PROTEIN, HUMAN; IFNG PROTEIN, HUMAN; IL15 PROTEIN, HUMAN; IL15RA PROTEIN, HUMAN; INTERLEUKIN 15 RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CELL MEDIATED CYTOTOXICITY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DAUDI CELL LINE; DENDRITIC CELL; ELECTROPORATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMIA REMISSION; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; CELL COMMUNICATION; CYTOTOXICITY; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; K-562 CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PHENOTYPE; PROCEDURES; REMISSION; SIGNAL TRANSDUCTION; TIME FACTOR; TRANSPLANTATION;

CANCER VACCINES; CELL COMMUNICATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ELECTROPORATION; GENETIC ENGINEERING; GRANZYMES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-15; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; PERFORIN; PHENOTYPE; RECEPTORS, INTERLEUKIN-15; REMISSION INDUCTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84953432234     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6536     Document Type: Article

References (51)

1. Finn OO and Banchereau J. Cancer vaccines: the state of the art. Semin Immunol. 2010; 22: 103-104.
2. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, Stein B, Smits EL, Schroyens WA, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010; 107: 13824-13829.
3. Palucka K, Ueno H and Banchereau J. Recent developments in cancer vaccines. J Immunol. 2011; 186: 1325-1331.
4. Anguille S, Lion E, Tel J, de Vries IJ, Coudere K, Fromm PD, Van Tendeloo VF, Smits EL and Berneman ZN. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One. 2012; 7: e51851.
5. Frankenberger B and Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol. 2012; 91: 53-58.
6. Subklewe M, Geiger C, Lichtenegger FS, Javorovic M, Kvalheim G, Schendel DJ and Bigalke I. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol Immunother. 2014; 63: 1093-1103.
7. Van Elssen CH, Oth T, Germeraad WT, Bos GM and Vanderlocht J. Natural killer cells: the secret weapon in dendritic cell vaccination strategies. Clin Cancer Res. 2014; 20: 1095-1103.
8. Pampena MB and Levy EM. Natural killer cells as helper cells in dendritic cell cancer vaccines. Front Immunol. 2015; 6: 13.
9. Bouwer AL, Saunderson SC, Caldwell FJ, Damani TT, Pelham SJ, Dunn AC, Jack RW, Stoitzner P and McLellan AD. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. J Immunol. 2014; 192: 2514-2521.
10. Lion E, Smits EL, Berneman ZN and Van Tendeloo VF. NK cells: key to success of DC-based cancer vaccines? Oncologist. 2012; 17: 1256-1270.
11. McLellan AD. A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy. Oncoimmunology. 2014; 3: e28582.
12. Croce M, Orengo AM, Azzarone B and Ferrini S. Immunotherapeutic applications of IL-15. Immunotherapy. 2012; 4: 957-969.
13. Jakobisiak M, Golab J and Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 2011; 22: 99-108.
14. Steel JC, Waldmann TA and Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012; 33: 35-41.
15. Burkett PR, Koka R, Chien M, Chai S, Boone DL and Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med. 2004; 200: 825-834.
16. Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA and Tagaya Y. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood. 2005; 105: 721-727.
17. Schluns KS, Stoklasek T and Lefrancois L. The roles of interleukin-15 receptor alpha: trans-presentation, receptor component, or both? Int J Biochem Cell Biol. 2005; 37: 1567-1571.
18. Lodolce JP, Burkett PR, Koka RM, Boone DL and Ma A. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 2002; 13: 429-439.
19. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD and Sprent J. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006; 103: 9166-9171.
20. Stoklasek TA, Schluns KS and Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol. 2006; 177: 6072-6080.
21. Van den Bergh JM, Van Tendeloo VF and Smits EL. Interleukin-15: new kid on the block for antitumor combination therapy. Cytokine Growth Factor Rev. 2015; 26: 15-24.
22. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 2008; 222: 357-368.
23. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC and Riddell SR. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 2009; 114: 2417-2426.
24. Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, Goldman CK, Bryant BR, Decker JM, Fleisher TA, Lane HC, Sneller MC, Kurlander RJ, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. 2011; 117: 4787-4795.
25. Waldmann T CK. (2012). First-in-Humans Study of New Immunotherapy Agent. NCI Cancer Bulletin.
26. Van Tendeloo VF, Ponsaerts P and Berneman ZN. mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther. 2007; 9: 423-431.
27. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C, Zhang GM, Patel V, Felber BK and Pavlakis GN. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem. 2008; 283: 4189-4199.
28. Dubois S, Patel HJ, Zhang M, Waldmann TA and Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol. 2008; 180: 2099-2106.
29. Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, Waldmann TA and Morris JC. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res. 2010; 70: 1072-1081.
30. Duitman EH, Orinska Z, Bulanova E, Paus R and Bulfone-Paus S. How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha. Mol Cell Biol. 2008; 28: 4851-4861.
31. Vanderlocht J, Van Elssen CH, Senden-Gijsbers BL, Meek B, Cloosen S, Libon C, Bos GM and Germeraad WT. Increased tumor-specific CD8+ T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-gamma. Int J Immunopathol Pharmacol. 2010; 23: 35-50.
32. Lucas M, Schachterle W, Oberle K, Aichele P and Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity. 2007; 26: 503-517.
33. Castillo EF, Stonier SW, Frasca L and Schluns KS. Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. J Immunol. 2009; 183: 4948-4956.
34. Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL and Butterfield LH. Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood. 2010; 116: 575-583.
35. Boudreau JE, Stephenson KB, Wang F, Ashkar AA, Mossman KL, Lenz LL, Rosenthal KL, Bramson JL, Lichty BD and Wan Y. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res. 2011; 71: 2497-2506.
36. Anguille S, Lion E, Van den Bergh J, Van Acker HH, Willemen Y, Smits EL, Van Tendeloo VF and Berneman ZN. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccin Immunother. 2013; 9: 1956-1961.
37. Zhang Y, Tian S, Liu Z, Zhang J, Zhang M, Bosenberg MW, Kedl RM, Waldmann TA, Storkus WJ, Falo LD, Jr. and You Z. Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. Oncoimmunology. 2014; 3: e959321.
38. Anguille S, Van Acker HH, Van den Bergh J, Willemen Y, Goossens H, Van Tendeloo VF, Smits EL, Berneman ZN and Lion E. Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. PLoS One. 2015; 10: e0123340.
39. Mortier E, Woo T, Advincula R, Gozalo S and Ma A. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med. 2008; 205: 1213-1225.
40. Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW and Turley SJ. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc Natl Acad Sci U S A. 2010; 107: 21647-21652.
41. Anguille S, Lion E, Smits E, Berneman ZN and van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin. 2011; 7: 579-584.
42. Lion E, Anguille S, Berneman ZN, Smits EL and Van Tendeloo VF. Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One. 2011; 6: e20952.
43. Anguille S, Willemen Y, Lion E, Smits EL and Berneman ZN. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy. 2012; 14: 647-656.
44. Lichtenegger FS, Krupka C, Kohnke T and Subklewe M. Immunotherapy for Acute Myeloid Leukemia. Semin Hematol. 2015; 52: 207-214.
45. Childs RW and Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Program. 2013; 2013: 234-246.
46. Guo Y, Luan L, Rabacal W, Bohannon JK, Fensterheim BA, Hernandez A and Sherwood ER. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-gamma. J Immunol. 2015; 195: 2353.
47. Lu J, Giuntoli RL, 2nd, Omiya R, Kobayashi H, Kennedy R and Celis E. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002; 8: 3877-3884.
48. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol. 2005; 175: 112-123.
49. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Tureci O and Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006; 108: 4009-4017.
50. Willemen Y, Van den Bergh JM, Lion E, Anguille S, Roelandts VA, Van Acker HH, Heynderickx SD, Stein BM, Peeters M, Figdor CG, Van Tendeloo VF, de Vries IJ, Adema GJ, et al. Engineering monocyte-derived dendritic cells to secrete interferon-alpha enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunol Immunother. 2015; 64: 831-842.
51. Van den Bergh JM, Guerti K, Willemen Y, Lion E, Cools N, Goossens H, Vorsters A, Van Tendeloo VF, Anguille S, Van Damme P and Smits EL. HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med. 2014; 18 : 1372-1380.